Vagus nerve stimulation: a new promising therapeutic tool in inflammatory bowel disease.

J Intern Med. July 2017;282(1):46-63.

B Bonaz¹, V Sinniger², S Pellissier³

¹ University Clinic of Hepato-Gastroenterology, University Hospital, Grenoble, France.; ² University Clinic of Hepato-Gastroenterology, University Hospital, Grenoble, France.; ³ University Clinic of Hepato-Gastroenterology, University Hospital, Grenoble, France.

Abstract

Inflammatory bowel disease (IBD), that is Crohn's disease (CD) and ulcerative colitis, affects about 1.5 million persons in the USA and 2.2 million in Europe. The pathophysiology of IBD involves immunological, genetic and environmental factors. The treatment is medico-surgical but suspensive. Anti-TNFα agents have revolutionized the treatment of IBD but have side effects. In addition, a non-negligible percentage of patients with IBD stop or take episodically their treatment. Consequently, a nondrug therapy targeting TNFα through a physiological pathway, devoid of major side effects and with a good cost-effectiveness ratio, would be of interest. The vagus nerve has dual anti-inflammatory properties through its afferent (i.e. hypothalamic-pituitary-adrenal axis) and efferent (i.e. the anti-TNFα effect of the cholinergic anti-inflammatory pathway) fibres. We have shown that there is an inverse relationship between vagal tone and plasma TNFα level in patients with CD, and have reported, for the first time, that chronic vagus nerve stimulation has anti-inflammatory properties in a rat model of colitis and in a pilot study performed in seven patients with moderate CD. Two of these patients failed to improve after 3 months of vagus nerve stimulation but five were in deep remission (clinical, biological and endoscopic) at 6 months of follow-up and vagal tone was restored. No major side effects were observed. Thus, vagus nerve stimulation provides a new therapeutic option in the treatment of CD.

Article Tools:

Medline

Email to me

Databanks:

GENBANK/NCT01569503
GENBANK/NCT02311660

Archives Highlights:

Duration of efficacy and effect of implant location in adult queens treated with a 9.4 mg deslorelin subcutaneous implant.
The average duration of action of the 9.4 mg deslorelin implant was 790 ± 155 days (range 525-1140 days) with no significant difference in duration or efficacy depending on implantation sites. The 9.4 mg deslorelin implant causes pharmacological sterilization for about 2 years in female cats, is fully reversible, and caused no clinically relevant side effects when administered at both interscapular and periumbilical sites.

Resolution of egg binding is possible in most client-owned parrots when multiple treatment strategies are considered.
Of the 150 events that had complete follow-up, 109 (72.7%) resulted in a successful outcome. A successful outcome was observed in 44 of 133 events (33.1%) that were initially managed medically without resorting to additional treatment strategies, in 31 events (86.1%) managed with mechanical assistance, in 20 events (60.6%) managed surgically, and in 12 events (85.7%) managed with ovocentesis.

The 4 prokinetic drugs metoclopramide, cisapride, pyridostigmine, and capromorelin do not increase fecal output or food intake in healthy New Zealand rabbits (Oryctolagus cuniculus).
Every day, rabbits produced a median of 75 g (range, 9 to 145 g) of feces, 226 fecal pellets (range, 12 to 412 pellets), and 151 mL (range, 5 to 420 mL) of urine. Metoclopramide, cisapride, pyridostigmine, and capromorelin had no effect on fecal production (both weight and number of pellets), food intake, urine production, or water intake compared to placebo at 24, 48, or 72 hours after administration.

Head tilt in 6 Ankole-Watusi cattle (Bos taurus ankole) with chronic exudative cornual sinusitis.
Clinically, 4 of the 6 cases had concurrent otitis at the time of initial clinical observation. Medical management was the standard across all cases with limited surgical success in 2 cases. Due to intractable and progressive clinical signs despite treatment attempts, euthanasia and postmortem examinations were performed.

Limb amputation for feline appendicular bone tumors results in excellent recovery outcomes and high owner satisfaction with a low incidence of complications.
Time to return to walking without support was < 3 days in 69.7% of cats and 3 to 7 days in 16.7%. Activity level changes were reported as no change in 75.8% of cats. There were no behavioral changes in 92.3% of cats. Quality of life following amputation was recorded as excellent in 82.4% of cats. Owner satisfaction was reported as very satisfied, moderately satisfied, or satisfied in 98.5% of cats.